A whistleblower has filed a lawsuit against the biotechnology company Amgen, Inc. for allegedly marketing the drugs Enbrel and Aranesp for illegal off-label use. The drugs are approved to treat rheumatoid arthritis and anemia respectively. Although physicians are allowed to prescribe medications for off-label use, it is illegal for drug manufacturers to market drugs for treatments that are not FDA approved.